SEARCH

SEARCH BY CITATION

References

  • 1
    Protonpompremmers. GIP/College voor zorgverzekeringen. Available at: http://www.gipdatabank.nl, accessed on 2005-06-18.
  • 2
    Geneesmiddeleninformatiebank. College ter Beoordeling Geneesmiddelen (CBG). Available at: http://www.cbg-meb.nl, accessed on 2005-08-02.
  • 3
    Multidisciplinaire Richtlijn Maagklachten. Utrecht: Kwaliteitsinstituut voor de Gezondheidszorg CBO en Nederlands Huisartsen Genootschap  (NHG), 2004.
  • 4
    Numans ME, De Wit NJ, Dirven JAM, et al. NHG-Standaad Maagklachten (tweede herziening). Huisarts Wet 2003; 46: 690700.
  • 5
    Richtlijn: NSAID-gebruik en preventie van maagschade. Utrecht: Kwaliteitsinstituut voor de Gezondheidszorg CBO, 2003.
  • 6
    Folmer H, Assendelft WJJ. NHG-Standpunt over de preventie van NSAID-geinduceerde maagproblemen en de plaats van de coxibs in de huisartenpraktijk: Nederlands Huisartsen Genootschap  (NHG); 2003. Available at: http://nhg.artsennet.nl, accessed on 2005-08-02.
  • 7
    Raghunath AS, O'Morain C, McLoughlin RC. Review article: The long-term use of proton-pump inhibitors. Aliment Pharmacol Ther 2005; 22 (Suppl. 1): 5563.
  • 8
    Gillen D, Wirz AA, McColl KEL. Helicobacter pylori eradication releases prolonged increased acid secretion following omeprazole treatment. Gastroenterology 2004; 126: 9808.
  • 9
    Laheij RJF, Sturkenboom MCJM, Hassing RJ, et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004; 292: 195560.
  • 10
    Dial S, Delaney JAC, Barkun A, et al. Use of gastric acid-depressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005; 294: 298995.
  • 11
    Hungin AP, Rubin GP, O'Flanagan H. Long-term prescribing of proton pump inhibitors in general practice. Br J Gen Pract 1999; 49: 4513.
  • 12
    Hungin AP, Rubin G, O'Flanagan H. Factors influencing compliance in long-term proton pump inhibitor therapy in general practice. Br J Gen Pract 1999; 49: 4634.
  • 13
    Bour B, Staub J-L, Chousterman M, et al. Long-term treatment of gastro-oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on-demand treatment compared with continuous treatment. Aliment Pharmacol Ther 2005; 21: 80512.
  • 14
    Bytzer P, Blum A, De Herdt D, Dubois D. Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease. Aliment Pharmacol Ther 2004; 20: 1818.
  • 15
    Talley NJ, Venables TL, Green JR, et al. Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months. Eur J Gastroenterol Hepatol 2002; 14: 85763.
  • 16
    Sjostedt S, Befrits R, Sylvan A, et al. Daily treatment with esomeprazole is superior to that taken on-demand for maintenance of healed erosive oesophagitis. Aliment Pharmacol Ther 2005; 22: 18391.
  • 17
    Bevolking per regio naar leeftijd, geslacht en burgerlijke staat: Centraal Bureau voor Statistiek. Available at: http://statline.cbs.nl, accessed on 2006-06-18.
  • 18
    Lamberts H, Wood M, Hofmans-Okkes IM. International primary care classifications: the effect of fifteen years of evolution. Fam Pract 1992; 9: 3309.
  • 19
    Anonymous. ATC and DDD Values. Geneva, Switzerland: World Health Organization, 1996.
  • 20
    Vlug AE, Van Der Lei J, Mosseveld BM, et al. Postmarketing surveillance based on electronic patient records: the IPCI project. Methods Inf Med 1999; 38: 33944.
  • 21
    Sturkenboom MCJM, Burke TA, Tangelder MJD, et al. Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2003; 18: 113747.
  • 22
    Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Levin R, Avorn J. The effects of initial drug choice and comorbidity on antihypertensive therapy compliance. Am J Hypertens 1997; 10: 697704.
  • 23
    Von  Korff M, Wagner EH, Saunders K. A Chronic Disease Score from automated pharmacy data. J Clin Epidemiol 1992; 45: 197203.
  • 24
    College Tarieven Gezondheidszorg Zorgautoriteit i.o. Available at: http://www.ctg-zaio.nl, accessed on 2005-06-02.
  • 25
    Schwizer W, Thumshirn M, Dent J, et al. Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial. Lancet 2001; 357: 173842.
  • 26
    Donnelan C, Sharma N, Preston C, Moayyedi P. Medical Treatments for the Maintenance Therapy of Reflux Oesophagitis and Endoscopic Negative Reflux Disease. The Cochrane Database of Systematic Reviews, 2004; 4.
  • 27
    Ouatu-Lascar R, Fitzgerald RC, Triadafilopoulos G. Differentiation and proliferation in Barrett's oesophagus and the effects of acid suppression. Gastroenterology 1999; 117: 32735.
  • 28
    El-Serag HB, Aguirre TV, Davis S, Kuebeler M, Bhattacharyya A, Sampliner RE. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's oesophagus. Am J Gastroenterol 2004; 99: 187783.
    Direct Link: